1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
3
|
Brana I and Siu LL: Locally advanced head
and neck squamous cell cancer: treatment choice based on risk
factors and optimizing drug prescription. Ann Oncol. 23(Suppl 10):
x178–x185. 2012. View Article : Google Scholar : PubMed/NCBI
|
4
|
Denis F, Garaud P, Bardet E, et al: Final
results of the 94-01 french head and neck oncology and radiotherapy
group randomized trial comparing radiotherapy alone with
concomitant radiochemotherapy in advanced-stage oropharynx
carcinoma. J Clin Oncol. 22:69–76. 2004. View Article : Google Scholar : PubMed/NCBI
|
5
|
Tribius S, Ihloff AS, Rieckmann T, et al:
Impact of HPV status on treatment of squamous cell cancer of the
oropharynx: What we know and what we need to know. Cancer Lett.
304:71–79. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
Edge S, Byrd DR, Compton CC, Fritz AG,
Greene FL and Trotti A: AJCC Cancer Staging Manual (7th). New York,
NY: Springer-Verlag. 2010.
|
7
|
Posner MR, Hershock DM, Blajman CR, et al:
Cisplatin and fluorouracil alone or with docetaxel in head and neck
cancer. N Engl J Med. 357:1705–1715. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Grégoire V, Ang K, Budach W, et al:
Delineation of the neck node levels for head and neck tumors: A
2013 update, DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG
consensus guidelines. Radiother Oncol. 110:172–181. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Gandini S, Botteri E, Iodice S, et al:
Tobacco smoking and cancer: A meta-analysis. Int J Cancer.
122:155–164. 2008. View Article : Google Scholar : PubMed/NCBI
|
10
|
Hashibe M, Brennan P, Benhamou S, et al:
Alcohol drinking in never users of tobacco, cigarette smoking in
never drinkers and the risk of head and neck cancer: pooled
analysis in the international head and neck cancer epidemiology
consortium. J Natl Cancer Inst. 99:777–789. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Friedman JM, Stavas MJ and Cmelak AJ:
Clinical and scientific impact of human papillomavirus on head and
neck cancer. World J Clin Oncol. 5:781–791. 2014. View Article : Google Scholar : PubMed/NCBI
|
12
|
Chung CH and Schwartz DL: Impact of
HPV-related head and neck cancer in clinical trials: Opportunity to
translate scientific insight into personalized care. Otolaryngol
Clin North Am. 45:795–806. 2012. View Article : Google Scholar : PubMed/NCBI
|
13
|
Ang KK, Harris J, Wheeler R, et al: Human
papillomavirus and survival of patients with oropharyngeal cancer.
N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
O'Rorke MA, Ellison MV, Murray LJ, et al:
Human papillomavirus related head and neck cancer survival: A
systematic review and meta-analysis. Oral Oncol. 48:1191–1201.
2012. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chaturvedi AK, Engels EA, Pfeiffer RM, et
al: Human papillomavirus and rising oropharyngeal cancer incidence
in the United States. J Clin Oncol. 29:4294–4301. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Stein AP, Saha S, Yu M, Kimple RJ and
Lambert PF: Prevalence of human papillomavirus in oropharyngeal
squamous cell carcinoma in the United States across time. Chem Res
Toxicol. 27:462–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
17
|
Marur S, Lee JW, Cmelak A, et al: A phase
II trial of induction chemotherapy followed by cetuximab with low
dose versus standard dose IMRT in patients with HPV-associated
resectable squamous cell carcinoma of the oropharynx (OP). J Clin
Oncol. 30(Suppl): ASCO Annual Meeting Abstract 5566. 2012.
|
18
|
Zur Hausen H: Papillomaviruses in the
causation of human cancers-a brief historical account. Virology.
384:260–265. 2009. View Article : Google Scholar : PubMed/NCBI
|
19
|
Wang MB, Liu IY, Gornbein JA and Nguyen
CT: HPV-Positive oropharyngeal carcinoma: A systematic review of
treatment and prognosis. Otolaryngol Head Neck Surg. Jun
29–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
20
|
Jin L and Xu ZX: Recent advances in the
study of HPV-associated carcinogenesis. Virol Sin. 30:101–106.
2015. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ramakrishnan S, Partricia S and Mathan G:
Overview of high-risk HPV's 16 and 18 infected cervical cancer:
Pathogenesis to prevention. Biomed Pharmacother. 70:103–110. 2015.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Vozenin MC, Lord HK, Hartl D and Deutsch
E: Unravelling the biology of human papillomavirus (HPV) related
tumours to enhance their radiosensitivity. Cancer Treat Rev.
36:629–636. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Jaboin JJ, Shinohara ET, Moretti L, et al:
The role of mTOR inhibition in augmenting radiation induced
autophagy. Technol Cancer Res Treat. 6:443–447. 2007. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gillison ML, Koch WM, Capone RB, et al:
Evidence for a causal association between human papillomavirus and
a subset of head and neck cancers. J Natl Cancer Inst. 92:709–720.
2000. View Article : Google Scholar : PubMed/NCBI
|
25
|
Blitzer GC, Smith MA, Harris SL and Kimple
RJ: Review of the clinical and biologic aspects of human
papillomavirus-positive squamous cell carcinomas of the head and
neck. Int J Radiat Oncol Biol Phys. 88:761–770. 2014. View Article : Google Scholar : PubMed/NCBI
|
26
|
Snow AN and Laudadio J: Human
papillomavirus detection in head and neck squamous cell carcinomas.
Adv Anat Pathol. 17:394–403. 2010. View Article : Google Scholar : PubMed/NCBI
|
27
|
Narisawa-Saito M and Kiyono T: Basic
mechanisms of high-risk human papillomavirus-induced
carcinogenesis: Roles of E6 and E7 proteins. Cancer Sci.
98:1505–1511. 2007. View Article : Google Scholar : PubMed/NCBI
|
28
|
Rischin D, Young RJ, Fisher R, et al:
Prognostic significance of p16INK4A and human papillomavirus in
patients with oropharyngeal cancer treated on TROG 02.02 phase III
trial. J Clin Oncol. 28:4142–4148. 2010. View Article : Google Scholar : PubMed/NCBI
|
29
|
Fakhry C, Westra WH, Li S, et al: Improved
survival of patients with human papillomavirus-positive head and
neck squamous cell carcinoma in a prospective clinical trial. J
Natl Cancer Inst. 100:261–269. 2008. View Article : Google Scholar : PubMed/NCBI
|
30
|
Ang KK and Sturgis EM: Human
papillomavirus as a marker of the natural history and response to
therapy of head and neck squamous cell carcinoma. Semin Radiat
Oncol. 22:128–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
31
|
Perrone F, Suardi S, Pastore E, et al:
Molecular and cytogenetic subgroups of oropharyngeal squamous cell
carcinoma. Clin Cancer Res. 12:6643–6651. 2006. View Article : Google Scholar : PubMed/NCBI
|
32
|
Gupta AK, Lee JH, Wilke WW, et al:
Radiation response in two HPV-infected head-and-neck cancer cell
lines in comparison to a non-HPV-infected cell line and
relationship to signaling through AKT. Int J Radiat Oncol Biol
Phys. 74:928–933. 2009. View Article : Google Scholar : PubMed/NCBI
|
33
|
Kamradt MC, Mohideen N and Vaughan AT:
RU486 increases radiosensitivity and restores apoptosis through
modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma
cells. Gynecol Oncol. 77:177–182. 2000. View Article : Google Scholar : PubMed/NCBI
|
34
|
Liu S, Song L, Zhang L, Zeng S and Gao F:
miR-21 modulates resistance of HR-HPV positive cervical cancer
cells to radiation through targeting LATS1. Biochem Biophys Res
Commun. 459:679–685. 2015. View Article : Google Scholar : PubMed/NCBI
|
35
|
Spanos WC, Nowicki P, Lee DW, et al:
Immune response during therapy with cisplatin or radiation for
human papillomavirus-related head and neck cancer. Arch Otolaryngol
Head Neck Surg. 135:1137–1146. 2009. View Article : Google Scholar : PubMed/NCBI
|
36
|
Nagel R, Martens-de Kemp SR, Buijze M, et
al: Treatment response of HPV-positive and HPV-negative head and
neck squamous cell carcinoma cell lines. Oral Oncol. 49:560–566.
2013. View Article : Google Scholar : PubMed/NCBI
|
37
|
Rieckmann T, Tribius S, Grob TJ, et al:
HNSCC cell lines positive for HPV and p16 possess higher cellular
radiosensitivity due to an impaired DSB repair capacity. Radiother
Oncol. 107:242–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
38
|
Arenz A, Ziemann F, Mayer C, et al:
Increased radiosensitivity of HPV-positive head and neck cancer
cell lines due to cell cycle dysregulation and induction of
apoptosis. Strahlenther Onkol. 190:839–846. 2014. View Article : Google Scholar : PubMed/NCBI
|
39
|
Kimple RJ, Smith MA, Blitzer GC, et al:
Enhanced radiation sensitivity in HPV-positive head and neck
cancer. Cancer Res. 73:4791–4800. 2013. View Article : Google Scholar : PubMed/NCBI
|
40
|
Andrei G, Snoeck R, Piette J, Delvenne P
and De Clercq E: Antiproliferative effects of acyclic nucleoside
phosphonates on human papillomavirus (HPV)-harboring cell lines
compared with HPV-negative cell lines. Oncol Res. 10:523–531.
1998.PubMed/NCBI
|
41
|
Abdulkarim B, Sabri S, Deutsch E, et al:
Antiviral agent Cidofovir restores p53 function and enhances the
radiosensitivity in HPV-associated cancers. Oncogene. 21:2334–2346.
2002. View Article : Google Scholar : PubMed/NCBI
|
42
|
Sirianni NI, Wang J and Ferris RL:
Antiviral activity of Cidofovir on a naturally human
papillomavirus-16 infected squamous cell carcinoma of the head and
neck (SCCHN) cell line improves radiation sensitivity. Oral Oncol.
41:423–428. 2005. View Article : Google Scholar : PubMed/NCBI
|
43
|
Pang E, Delic NC, Hong A, Zhang M, Rose BR
and Lyons JG: Radiosensitization of oropharyngeal squamous cell
carcinoma cells by human papillomavirus 16 oncoprotein E6*I. Int J
Radiat Oncol Biol Phys. 79:860–865. 2011. View Article : Google Scholar : PubMed/NCBI
|
44
|
Fu YJ, Liu SX and Xian JM: Combination of
adenovirus p16(INK4A) gene therapy and ionizing radiation for
laryngeal squamous cell carcinoma. Sichuan Da Xue Xue Bao Yi Xue
Ban. 35:209–211. 2004.(In Chinese). PubMed/NCBI
|
45
|
Coppock JD, Wieking BG, Molinolo AA, et
al: Improved clearance during treatment of HPV-positive head and
neck cancer through mTOR inhibition. Neoplasia. 15:620–630. 2013.
View Article : Google Scholar : PubMed/NCBI
|
46
|
Sørensen BS, Busk M, Olthof N, et al:
Radiosensitivity and effect of hypoxia in HPV positive head and
neck cancer cells. Radiother Oncol. 108:500–505. 2013. View Article : Google Scholar : PubMed/NCBI
|
47
|
Gubanova E, Brown B, Ivanov SV, et al:
Downregulation of SMG-1 in HPV-positive head and neck squamous cell
carcinoma due to promoter hypermethylation correlates with improved
survival. Clin Cancer Res. 18:1257–1267. 2012. View Article : Google Scholar : PubMed/NCBI
|
48
|
Brumbaugh KM, Otterness DM, Geisen C, et
al: The mRNA surveillance protein hSMG-1 functions in genotoxic
stress response pathways in mammalian cells. Mol Cell. 14:585–598.
2004. View Article : Google Scholar : PubMed/NCBI
|
49
|
Vermeer DW, Spanos WC, Vermeer PD, et al:
Radiation-induced loss of cell surface CD47 enhances
immune-mediated clearance of human papillomavirus-positive cancer.
Int J Cancer. 133:120–129. 2013. View Article : Google Scholar : PubMed/NCBI
|
50
|
Wieking BG, Vermeer DW, Spanos WC, Lee KM,
Vermeer P, Lee WT, Xu Y, Gabitzsch ES, Balcaitis S, Balint JP Jr,
et al: A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of
HPV expressing tumors. Cancer Gene Ther. 19:667–674. 2012.
View Article : Google Scholar : PubMed/NCBI
|
51
|
Gillet JP, Calcagno AM, Varma S, Marino M,
Green LJ, Vora MI, Patel C, Orina JN, Eliseeva TA, Singal V, et al:
Redefining the relevance of established cancer cell lines to the
study of mechanisms of clinical anti-cancer drug resistance. Proc
Natl Acad Sci USA. 108:18708–18713. 2011. View Article : Google Scholar : PubMed/NCBI
|
52
|
Uva P, Lahm A, Sbardellati A, Grigoriadis
A, Tutt A and de Rinaldis E: Comparative membranome expression
analysis in primary tumors and derived cell lines. PLoS One.
5:e117422010. View Article : Google Scholar : PubMed/NCBI
|
53
|
Kimple RJ, Harari PM, Torres AD, Yang RZ,
Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, et
al: Development and characterization of HPV-positive and
HPV-negative head and neck squamous cell carcinoma tumorgrafts.
Clin Cancer Res. 19:855–864. 2013. View Article : Google Scholar : PubMed/NCBI
|
54
|
Haraf DJ, Nodzenski E, Brachman D, Mick R,
Montag A, Graves D, Vokes EE and Weichselbaum RR: Human papilloma
virus and p53 in head and neck cancer: clinical correlates and
survival. Clin Cancer Res. 2:755–762. 1996.PubMed/NCBI
|
55
|
Mellin H, Friesland S, Lewensohn R, et al:
Human papillomavirus (HPV) DNA in tonsillar cancer: clinical
correlates, risk of relapse and survival. Int J Cancer. 89:300–304.
2000. View Article : Google Scholar : PubMed/NCBI
|
56
|
Schwartz SR, Yueh B, McDougall JK, Daling
JR and Schwartz SM: Human papillomavirus infection and survival in
oral squamous cell cancer: a population-based study. Otolaryngol
Head Neck Surg. 125:1–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
57
|
Lindel K, Beer KT, Laissue J, Greiner RH
and Aebersold DM: Human papillomavirus positive squamous cell
carcinoma of the oropharynx: a radiosensitive subgroup of head and
neck carcinoma. Cancer. 92:805–813. 2001. View Article : Google Scholar : PubMed/NCBI
|
58
|
Weinberger PM, Yu Z, Haffty BG, et al:
Molecular classification identifies a subset of human
papillomavirus-associated oropharyngeal cancers with favorable
prognosis. J Clin Oncol. 24:736–747. 2006. View Article : Google Scholar : PubMed/NCBI
|
59
|
Ragin CC and Taioli E: Survival of
squamous cell carcinoma of the head and neck in relation to human
papillomavirus infection: Review and meta-analysis. Int J Cancer.
121:1813–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
60
|
Posner MR, Lorch JH, Goloubeva O, et al:
Survival and human papillomavirus in oropharynx cancer in TAX 324:
A subset analysis from an international phase III trial. Ann Oncol.
22:1071–1077. 2011. View Article : Google Scholar : PubMed/NCBI
|
61
|
Lassen P, Eriksen JG, Krogdahl A, et al:
The influence of HPV-associated p16-expression on accelerated
fractionated radiotherapy in head and neck cancer: Evaluation of
the randomised DAHANCA 6&7 trial. Radiother Oncol. 100:49–55.
2011. View Article : Google Scholar : PubMed/NCBI
|
62
|
Marur S, D'Souza G, Westra WH and
Forastiere AA: HPV-associated head and neck cancer: a virus-related
cancer epidemic. Lancet Oncol. 11:781–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
63
|
National Comprehensive Cancer Network
(NCCN): Clinical Practice Guidelines in Oncology. Head and neck
cancer. Version 1. 2015.Available at. http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdfAccessed.
September 13–2015
|
64
|
Jemal A, Simard EP, Dorell C, Noone AM,
Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D, et
al: Annual Report to the Nation on the Status of Cancer, 1975–2009,
featuring the burden and trends in human papillomavirus
(HPV)-associated cancers and HPV vaccination coverage levels. J
Natl Cancer Inst. 105:175–201. 2013. View Article : Google Scholar : PubMed/NCBI
|
65
|
Coordes A, Lenz K, Qian X, Lenarz M,
Kaufmann AM and Albers AE: Meta-analysis of survival in patients
with HNSCC discriminates risk depending on combined HPV and p16
status. Eur Arch Otorhinolaryngol. July 31–2015.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
66
|
Gao G, Gay HA, Chernock RD, Zhang TR, Luo
J, Thorstad WL, Lewis JS Jr and Wang X: A microRNA expression
signature for the prognosis of oropharyngeal squamous cell
carcinoma. Cancer. 119:72–80. 2013. View Article : Google Scholar : PubMed/NCBI
|